162 related articles for article (PubMed ID: 32425598)
1. Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma.
Kang X; Bai L; Han C; Qi X
Cancer Manag Res; 2020; 12():2839-2851. PubMed ID: 32425598
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus-associated diffuse large B-cell lymphoma: unique clinical features, poor outcome, and hepatitis B surface antigen-driven origin.
Deng L; Song Y; Young KH; Hu S; Ding N; Song W; Li X; Shi Y; Huang H; Liu W; Zheng W; Wang X; Xie Y; Lin N; Tu M; Ping L; Ying Z; Zhang C; Sun Y; Zhu J
Oncotarget; 2015 Sep; 6(28):25061-73. PubMed ID: 26314957
[TBL] [Abstract][Full Text] [Related]
4. Clinical analysis and prognostic significance of hepatitis B virus infections for diffuse large B-cell lymphoma with or without rituximab therapy.
Xie W; Zhou D; Hu K; Xiao X; Huang W; He J; Shi J; Luo Y; Zhang J; Lin M; Cai Z; Huang H; Ye X
Exp Ther Med; 2013 Jul; 6(1):109-114. PubMed ID: 23935730
[TBL] [Abstract][Full Text] [Related]
5. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological and prognostic features of hepatitis B virus-associated diffuse large B-cell lymphoma: a single-center retrospective study in China.
Chen DG; Chen G; Wang C; Ke LF; Wu H; He HM; Yang Y; Chen YP
Infect Agent Cancer; 2021 Aug; 16(1):57. PubMed ID: 34404436
[TBL] [Abstract][Full Text] [Related]
7. Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma.
Wang Y; Wang H; Pan S; Hu T; Shen J; Zheng H; Xie S; Xie Y; Lu R; Guo L
J Cancer; 2018; 9(9):1575-1581. PubMed ID: 29760795
[No Abstract] [Full Text] [Related]
8. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study.
Kim JH; Bang YJ; Park BJ; Yoo T; Kim CW; Kim TY; Heo DS; Lee HS; Kim NK
Jpn J Cancer Res; 2002 May; 93(5):471-7. PubMed ID: 12036441
[TBL] [Abstract][Full Text] [Related]
9. Splenic large B-cell lymphoma in patients with hepatitis C virus infection.
Takeshita M; Sakai H; Okamura S; Oshiro Y; Higaki K; Nakashima O; Uike N; Yamamoto I; Kinjo M; Matsubara F
Hum Pathol; 2005 Aug; 36(8):878-85. PubMed ID: 16112004
[TBL] [Abstract][Full Text] [Related]
10. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma.
Wang F; Xu RH; Luo HY; Zhang DS; Jiang WQ; Huang HQ; Sun XF; Xia ZJ; Guan ZZ
BMC Cancer; 2008 Apr; 8():115. PubMed ID: 18433487
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival.
Chen KL; Chen J; Rao HL; Guo Y; Huang HQ; Zhang L; Shao JY; Lin TY; Jiang WQ; Zou DH; Hu LY; Wirian ML; Cai QQ
Chin J Cancer; 2015 May; 34(5):225-34. PubMed ID: 26058465
[TBL] [Abstract][Full Text] [Related]
12. Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.
Yan X; Zhou M; Lou Z; Mu Q; Sheng L; Zhang P; Wang Y; Ouyang G
J Cancer Res Ther; 2018; 14(Supplement):S248-S253. PubMed ID: 29578182
[TBL] [Abstract][Full Text] [Related]
13. Antiviral prophylaxis for hepatitis B carriers improves the prognosis of diffuse large B-cell lymphoma in Taiwan - a population-based study.
Huang HH; Hsiao FY; Chen HM; Wang CY; Ko BS
Br J Haematol; 2021 Jan; 192(1):110-118. PubMed ID: 33131074
[TBL] [Abstract][Full Text] [Related]
14. Concurrent and reactivation of hepatitis B virus infection in diffuse large B-cell lymphoma: risk factors and survival outcome.
Guo YF; Pan JX; Zhuang WH
Infect Agent Cancer; 2018; 13():40. PubMed ID: 30559832
[TBL] [Abstract][Full Text] [Related]
15. A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China.
Zhang JY; Dai M; Wang X; Lu WQ; Li DS; Zhang MX; Wang KJ; Dai LP; Han SG; Zhou YF; Zhuang H
Int J Epidemiol; 1998 Aug; 27(4):574-8. PubMed ID: 9758109
[TBL] [Abstract][Full Text] [Related]
16. Both chronic HBV infection and naturally acquired HBV immunity confer increased risks of B-cell non-Hodgkin lymphoma.
Zhou X; Pan H; Yang P; Ye P; Cao H; Zhou H
BMC Cancer; 2019 May; 19(1):477. PubMed ID: 31113483
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
20. HBV-associated DLBCL of poor prognosis: advance in pathogenesis, immunity and therapy.
Wan X; Young KH; Bai O
Front Immunol; 2023; 14():1216610. PubMed ID: 37483605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]